News | October 31, 2012

Sildenafil Citrate Improves Sexual Function of Prostate Radiation Therapy Patients

Prostate Technology Radiation Oncology Clinical Trial/Study ASTRO

October 31, 2012 — Sildenafil citrate (SC), a phosphodiesterase type 5 inhibitor, administered before, during and after radiation therapy improved overall sexual function of prostate cancer patients, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting.

This is the first prospective, randomized, double-blind, placebo controlled trial to determine if daily, adjuvant use of SC before, during and after radiation therapy preserves erectile function in prostate cancer patients. The study included 290 patients with clinically localized prostate cancer who were treated with external beam radiation therapy and/or permanent interstitial implantation and were randomly assigned to two groups (2:1 randomization): those who received a 50 mg dose daily of SC, and those who received a placebo.

Patients in both groups were asked to complete the international index of erectile function (IIEF) and international prostate symptom score (IPSS) questionnaires before therapy and at six, 12 and 24 months after radiation treatment. Results from 144 patients, those who completed the surveys before therapy and at least one additional time period, indicate that those in the SC group experienced improved overall sexual function compared to the placebo group at all time points, accounting for IIEF scores of 58.6 vs. 49.4, 56.3 vs. 48.2 and 54.9 vs. 47.6, respectively. Patient characteristics including age, use of brachytherapy, androgen deprivation therapy and baseline IIEF scores were similar in both treatment groups.

Patients received medication three days before their radiation treatment and continued with a daily dose for six months, after which daily use of SC or the placebo was discontinued and taken on an as-needed basis only. IIEF scores were based on patient feedback about their erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction.

“Our study found that prostate cancer patients treated with sildenafil citrate and adjuvant radiation treatment had improved overall erectile function and overall satisfaction of their sexual activity and function,” said Michael J. Zelefsky, M.D., lead author of the study and a radiation oncologist at Memorial Sloan-Kettering Cancer Center in New York. “The most significant improvements were seen at six and 12 months following treatment, with a slight dip at the 24-month mark, suggesting that future trials need to be conducted to demonstrate if a longer treatment duration can further improve patient outcomes.”

The abstract, “Results of a Prospective Randomized Double-blind Placebo Controlled Trial Evaluating the Use Prophylactic Sildenafil Citrate During Radiation Therapy in the Treatment of Prostate Cancer,” was presented in detail during a scientific session at ASTRO’s 54th Annual Meeting on Monday, Oct. 29, 2012.

For more information:

Related Content

Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
MRI Effective for Monitoring Liver Fat in Obese Patients
News | Magnetic Resonance Imaging (MRI) | December 28, 2018
Magnetic resonance imaging (MRI) provides a safe, noninvasive way to monitor liver fat levels in people who undergo...
Heart Attack, Stroke Risks Increase Leading Up to Cancer Diagnosis
News | Cardio-oncology | December 21, 2018
Older adults with cancer are more likely to have had a heart attack or stroke in the months prior to their cancer...